ALKS News & Analysis
3 articles
Market Mood
Alkermes (ALKS) Price Target Increased After Narcolepsy Drug Data
Needham has raised the price target for Alkermes (ALKS) following positive data on its narcolepsy drug. The new target reflects optimism surrounding the drug's performance and its potential market impact. The stock's performance may see changes based on analysts' expectations, particularly in the context of treatment advancements for narcolepsy. Increased investor interest can affect trading volumes as news circulates about this pivotal milestone.
Read More: Alkermes (ALKS) Price Target Increased After Narcolepsy Drug Data
Alkermes (ALKS) Quarterly Loss Narrows, Beat Analysts' Estimates
Alkermes (ALKS) reported a narrower quarterly loss, which was below analysts' expectations. The company's performance surpassed estimates, indicating potential improvement in financial health. This positive result may influence investor confidence moving forward. Specific figures of the loss and estimates were not provided in the article.
Read More: Alkermes (ALKS) Quarterly Loss Narrows, Beat Analysts' Estimates
Alkermes (ALKS) Stock Price Target Raised to $53 by Mizuho
Mizuho increased its price target for Alkermes (ALKS) to $53, attributing the change to improved confidence in the company's drug pipeline. This revision reflects optimism regarding potential therapeutic advancements. The adjustment is significant for investors monitoring ALKS, as price targets can influence market sentiment and trading decisions. Increased confidence in drug development may correlate with higher stock valuations moving forward.
Read More: Alkermes (ALKS) Stock Price Target Raised to $53 by Mizuho